HOSPITAL UNIVERSITARIO RUBER
Departamento
KU Leuven
Lovaina, BélgicaPublicaciones en colaboración con investigadores/as de KU Leuven (22)
2024
-
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes
Journal of Clinical Oncology, Vol. 42, Núm. 9, pp. 987-993
2023
-
Correction to: Improving clinical paediatric research and learning from COVID-19: recommendations by the Conect4Children expert advice group (Pediatric Research, (2022), 91, 5, (1069-1077), 10.1038/s41390-021-01587-3)
Pediatric Research
-
XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease
Breast Cancer Research, Vol. 25, Núm. 1
2022
-
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
Journal of Clinical Oncology, Vol. 32
-
Improving clinical paediatric research and learning from COVID-19: recommendations by the Conect4Children expert advice group
Pediatric Research, Vol. 91, Núm. 5, pp. 1069-1077
-
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer
Cancer Treatment Reviews, Vol. 111
-
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis
npj Breast Cancer, Vol. 8, Núm. 1
-
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer
npj Breast Cancer, Vol. 8, Núm. 1
2021
-
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
Breast Cancer Research, Vol. 23, Núm. 1
-
Anthracyclines strike back: Rediscovering non‐pegylated liposomal doxorubicin in current therapeutic scenarios of breast cancer
Cancers, Vol. 13, Núm. 17
-
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
Annals of Oncology, Vol. 32, Núm. 9, pp. 1148-1156
-
Expected medium- And long-term impact of the COVID-19 outbreak in oncology
JCO Global Oncology, Vol. 7, pp. 162-172
-
Sacituzumab govitecan in metastatic triple-negative breast cancer
New England Journal of Medicine, Vol. 384, Núm. 16, pp. 1529-1541
-
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer
Breast Cancer Research and Treatment, Vol. 187, Núm. 1, pp. 155-165
-
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
npj Breast Cancer, Vol. 7, Núm. 1
2020
-
Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR1, HER22, node-positive, high-risk, early breast cancer (monarchE)
Journal of Clinical Oncology, Vol. 38, Núm. 34, pp. 3987-3998
-
Oncological care organisation during COVID-19 outbreak
ESMO Open, Vol. 5, Núm. 4
-
Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1
Breast Cancer Research and Treatment, Vol. 184, Núm. 1, pp. 161-172
-
Reimagining global oncology clinical trials for the postpandemic era: A call to arms
JCO Global Oncology, pp. 1357-1362
2018
-
Multiple modes of action of eribulin mesylate: Emerging data and clinical implications
Cancer Treatment Reviews, Vol. 70, pp. 190-198